Biblio

Author Title Type [ Year(Asc)]
Filters: Author is He, Xin  [Clear All Filters]
2023
Huan Y, Zhou D, Wu X, He X, Chen H, Li S, Jia B, Dou Y, Fei X, Wu S, et al. 3D bioprinted autologous bone particle scaffolds for cranioplasty promote bone regeneration with both implanted and native BMSCs. Biofabrication. 2023.
Huang F, Sun J, Chen W, Zhang L, He X, Dong H, Wu Y, Wang H, Li Z, Ball B, et al. Correction: TET2 deficiency promotes MDS-associated leukemogenesis. Blood Cancer J. 2023;13(1):174.
He X, Feng W. Identification and Validation of NK Marker Genes in Ovarian Cancer by scRNA-seq Combined with WGCNA Algorithm. Mediators Inflamm. 2023;2023:6845701.
Zhu J, He X, Bernard D, Shen J, Su Y, Molek A, Issacs B, Mishra N, Tian X, Garmendia A, et al. Identification of New Compounds against PRRSV Infection by Directly Targeting CD163. J Virol. 2023:e0005423.
Chen Z, Zhou K, Xue J, Small A, Xiao G, Nguyen LXuan Truon, Zhang Z, Prince E, Weng H, Huang H, et al. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. Sci Transl Med. 2023;15(689):eabq8513.
Yang Y, Yang R, Kang B, Qian S, He X, Zhang X. Single-cell long-read sequencing in human cerebral organoids uncovers cell-type-specific and autism-associated exons. Cell Rep. 2023;42(11):113335.
Gong X, Zhang Y, He X, Moloudizargari M, Yu T, Wang L, Liu W, Jin L, Xu H, Xu Y, et al. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.